{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:6607"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:6607","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Development of MHC class II-restricted TCR gene therapy for epstein barr virus associated malignancies","abstract":"CD4+ T-cells play a pivotal role within the immune response, and multiple studies have highlighted their importance in anti-tumour immunity. TCR gene transfer is a successful method of specifically redirecting T-cell specificity. We have therefore investigated the anti tumour potential of EBV-specific MHC class II restricted T-cells, generated by this approach. We have identified and cloned a DR52b-restricted TCR, specific for an EBNA2 derived peptide (PRS), which is expressed in Post-Transplant Lymphoproliferative Disease (PTLD) and some other EBV-associated malignancies. We have shown that the TCR is functional in both CD4+ and CD8+ T-cells, with transduced T-cells specifically recognising the PRS-peptide with a high avidity. Transduced T-cells have been shown to proliferate, produce multiple cytokines and have direct cytotoxic capacity in response to physiological levels of EBNA2 processed and presented by EBV-infected B-cells. Additionally to this direct response, CD4+ T-cells retain helper functions. Importantly, transduced T-cells have shown hints of tumour control \\(in\\) \\(vivo\\). Results from this study highlight that TCR gene transfer with EBV-specific MHC class II restricted TCRs can generate polyclonal T-cells with functional capacity against virus infected cells. PRS specific TCR gene transfer may thus be useful in rapid generation of T cells for treatment of PTLD. Given the importance of CD4+ T-cells for anti-tumour responses, this study also highlights the potential for using TCR gene transfer to target these cells towards other MHC class II-positive tumours.","abstract_html":"CD4+ T-cells play a pivotal role within the immune response, and multiple studies have highlighted their importance in anti-tumour immunity. TCR gene transfer is a successful method of specifically redirecting T-cell specificity. We have therefore investigated the anti tumour potential of EBV-specific MHC class II restricted T-cells, generated by this approach. We have identified and cloned a DR52b-restricted TCR, specific for an EBNA2 derived peptide (PRS), which is expressed in Post-Transplant Lymphoproliferative Disease (PTLD) and some other EBV-associated malignancies. We have shown that the TCR is functional in both CD4+ and CD8+ T-cells, with transduced T-cells specifically recognising the PRS-peptide with a high avidity. Transduced T-cells have been shown to proliferate, produce multiple cytokines and have direct cytotoxic capacity in response to physiological levels of EBNA2 processed and presented by EBV-infected B-cells. Additionally to this direct response, CD4+ T-cells retain helper functions. Importantly, transduced T-cells have shown hints of tumour control \\(in\\) \\(vivo\\). Results from this study highlight that TCR gene transfer with EBV-specific MHC class II restricted TCRs can generate polyclonal T-cells with functional capacity against virus infected cells. PRS specific TCR gene transfer may thus be useful in rapid generation of T cells for treatment of PTLD. Given the importance of CD4+ T-cells for anti-tumour responses, this study also highlights the potential for using TCR gene transfer to target these cells towards other MHC class II-positive tumours.","abstract_has_math":true,"creators":["Williams, Anna"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-07","date_published":"2016-07","updated_at":"2026-11-19T09:28:58Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/6607/1/Williams16PhD_Redacted.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A6607","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Williams, Anna"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2016-07"]},{"key":"dc:date.issued","label":"Date","values":["2016-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer Studies"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/6607/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/6607/1/Williams16PhD_Redacted.pdf","http://etheses.bham.ac.uk//id/eprint/6607/2/Decl_IS_Williams16PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["CD4+ T-cells play a pivotal role within the immune response, and multiple studies have highlighted their importance in anti-tumour immunity. TCR gene transfer is a successful method of specifically redirecting T-cell specificity. We have therefore investigated the anti tumour potential of EBV-specific MHC class II restricted T-cells, generated by this approach. We have identified and cloned a DR52b-restricted TCR, specific for an EBNA2 derived peptide (PRS), which is expressed in Post-Transplant Lymphoproliferative Disease (PTLD) and some other EBV-associated malignancies. We have shown that the TCR is functional in both CD4+ and CD8+ T-cells, with transduced T-cells specifically recognising the PRS-peptide with a high avidity. Transduced T-cells have been shown to proliferate, produce multiple cytokines and have direct cytotoxic capacity in response to physiological levels of EBNA2 processed and presented by EBV-infected B-cells. Additionally to this direct response, CD4+ T-cells retain helper functions. Importantly, transduced T-cells have shown hints of tumour control \\(in\\) \\(vivo\\). Results from this study highlight that TCR gene transfer with EBV-specific MHC class II restricted TCRs can generate polyclonal T-cells with functional capacity against virus infected cells. PRS specific TCR gene transfer may thus be useful in rapid generation of T cells for treatment of PTLD. Given the importance of CD4+ T-cells for anti-tumour responses, this study also highlights the potential for using TCR gene transfer to target these cells towards other MHC class II-positive tumours."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Development of MHC class II-restricted TCR gene therapy for epstein barr virus associated malignancies"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Williams, Anna"],"dc:date":["2016-07"],"dc:date.issued":["2016-07"],"dc:description.abstract":["CD4+ T-cells play a pivotal role within the immune response, and multiple studies have highlighted their importance in anti-tumour immunity. TCR gene transfer is a successful method of specifically redirecting T-cell specificity. We have therefore investigated the anti tumour potential of EBV-specific MHC class II restricted T-cells, generated by this approach. We have identified and cloned a DR52b-restricted TCR, specific for an EBNA2 derived peptide (PRS), which is expressed in Post-Transplant Lymphoproliferative Disease (PTLD) and some other EBV-associated malignancies. We have shown that the TCR is functional in both CD4+ and CD8+ T-cells, with transduced T-cells specifically recognising the PRS-peptide with a high avidity. Transduced T-cells have been shown to proliferate, produce multiple cytokines and have direct cytotoxic capacity in response to physiological levels of EBNA2 processed and presented by EBV-infected B-cells. Additionally to this direct response, CD4+ T-cells retain helper functions. Importantly, transduced T-cells have shown hints of tumour control \\(in\\) \\(vivo\\). Results from this study highlight that TCR gene transfer with EBV-specific MHC class II restricted TCRs can generate polyclonal T-cells with functional capacity against virus infected cells. PRS specific TCR gene transfer may thus be useful in rapid generation of T cells for treatment of PTLD. Given the importance of CD4+ T-cells for anti-tumour responses, this study also highlights the potential for using TCR gene transfer to target these cells towards other MHC class II-positive tumours."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/6607/1/Williams16PhD_Redacted.pdf","http://etheses.bham.ac.uk//id/eprint/6607/2/Decl_IS_Williams16PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer Studies"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/6607/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Development of MHC class II-restricted TCR gene therapy for epstein barr virus associated malignancies"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:28:58Z"}